{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:05:13Z","timestamp":1791975913624,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.esmoop.2024.102941","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T12:35:03Z","timestamp":1709728503000},"page":"102941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials"],"prefix":"10.1016","volume":"9","author":[{"given":"L.","family":"Arenare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4511-7969","authenticated-orcid":false,"given":"R.","family":"Di Liello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1979-5400","authenticated-orcid":false,"given":"P.","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gridelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Nuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6188-5664","authenticated-orcid":false,"given":"A.","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schettino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gravina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chiodini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-3785","authenticated-orcid":false,"given":"M.","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-0526","authenticated-orcid":false,"given":"F.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9519-4757","authenticated-orcid":false,"given":"M.C.","family":"Piccirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.102941_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","article-title":"Patient-reported outcomes in the evaluation of toxicity of anticancer treatments","volume":"13","author":"Di Maio","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102941_bib2","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2004.03.025","article-title":"How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30","volume":"22","author":"Fromme","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102941_bib3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Di Maio","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102941_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx029","article-title":"Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients","volume":"109","author":"Denis","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2024.102941_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.esmoop.2024.102941_bib6","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102941_bib7","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1200\/JCO.2009.25.4433","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study","volume":"28","author":"Colucci","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102941_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.lungcan.2008.05.027","article-title":"Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial","volume":"63","author":"Gebbia","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2024.102941_bib9","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/sj.bjc.6603096","article-title":"Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial","volume":"94","author":"Pacilio","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2024.102941_bib10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(07)70146-8","article-title":"Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study","volume":"8","author":"Gridelli","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.102941_bib11","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2011.41.2056","article-title":"First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial","volume":"30","author":"Gridelli","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102941_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2013.04.008","article-title":"Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study","volume":"81","author":"Morabito","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2024.102941_bib13","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","article-title":"Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study","volume":"35","author":"Pignata","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102941_bib14","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2017.76.8390","article-title":"Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: Joint analysis of MILES-3 and MILES-4 phase III trials","volume":"36","author":"Gridelli","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102941_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12885-016-2102-y","article-title":"A\u00a0randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX\/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)","volume":"16","author":"Avallone","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2024.102941_bib16","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2022.05.008","article-title":"Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous NSCLC: the BEVERLY Multicenter Randomized Phase 3 Trial","volume":"17","author":"Piccirillo","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2024.102941_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12874-018-0535-5","article-title":"Simulation shows undesirable results for competing risks analysis with time-dependent covariates for clinical outcomes","volume":"18","author":"Poguntke","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.esmoop.2024.102941_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00280-010-1487-6","article-title":"Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy","volume":"68","author":"Shitara","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2024.102941_bib19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40265-018-0909-3","article-title":"Chemotherapy-induced neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients","volume":"78","author":"Kasi","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.esmoop.2024.102941_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1186\/s12885-021-08323-4","article-title":"Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials","volume":"21","author":"Gargiulo","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2024.102941_bib21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(05)70255-2","article-title":"Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials","volume":"6","author":"Di Maio","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.102941_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ygyno.2019.04.012","article-title":"Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials","volume":"154","author":"Daniele","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2024.102941_bib23","doi-asserted-by":"crossref","first-page":"432","DOI":"10.21037\/tlcr-21-938","article-title":"The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy","volume":"11","author":"Badaoui","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.esmoop.2024.102941_bib24","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1158\/1078-0432.CCR-23-0396","article-title":"Patient-reported outcomes as inter-radiographic predictors of response in non-small cell lung cancer","volume":"29","author":"Bhatt","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.102941_bib25","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/cam4.4692","article-title":"Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma: analysis of 1239 patients from the GOYA study","volume":"11","author":"Huang","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.esmoop.2024.102941_bib26","doi-asserted-by":"crossref","first-page":"e1246","DOI":"10.1200\/OP.20.01096","article-title":"Association of fatigue and outcomes in advanced cancer: an analysis of four SWOG treatment trials","volume":"17","author":"Mo","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.esmoop.2024.102941_bib27","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","article-title":"The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline","volume":"33","author":"Di Maio","year":"2022","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1016\/j.esmoop.2024.103693","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000}}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924007099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924007099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:32:05Z","timestamp":1761856325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924007099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2059702924007099"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102941","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102941","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102941"}}